GeneDx Holdings Corp.
- Open
- 83.84
- Day high
- 85.20
- Day low
- 83.46
- Prev close
- 84.81
- Volume
- 37K
- Mkt cap
- $2.5B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 10.2
- P/S
- 5.5
- Yield
- —
- Per share
- —
- ▲Insiders net buying $10.0M over the last 3 months (2 open-market buys, 8 sales)
- 🏛Institutions accumulating (13F)
GeneDx Holdings Corp. (WGS) is a Healthcare company listed on NASDAQ. The stock is down 35% over the past year. Over the trailing 3 months, insiders filed 2 open-market buys and 8 sales (SEC Form 4).
GeneDx Holdings Corp. (WGS) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 4 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
WGS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 3, 2026 | $-0.19 | $0.01 | +105.3% | $114M | +3.1% |
| May 4, 2026 | $-0.06 | $-0.28 | -366.7% | $102M | -9.1% |
| Feb 23, 2026 | $0.11 | $0.14 | +27.3% | $121M | +5.1% |
| Jul 29, 2025 | $0.10 | $0.50 | +400.0% | $103M | +4.1% |
| Apr 30, 2025 | $0.11 | $0.28 | +154.5% | $87M | +2.1% |
| Feb 18, 2025 | $0.04 | $0.70 | +1650.0% | $96M | +21.1% |
| Feb 20, 2024 | $-0.60 | $-0.59 | +1.7% | $57M | +3.6% |
| Mar 14, 2023 | $-0.16 | $-0.25 | -56.3% | $61M | -13.5% |
| Nov 14, 2022 | $-0.21 | $-0.20 | +4.8% | $83M | +22.9% |
| Aug 15, 2022 | $-0.21 | $-0.25 | -19.0% | $36M | -46.5% |
| May 12, 2022 | $-0.31 | $-0.31 | +0.0% | $54M | +13.6% |
| Mar 14, 2022 | $-0.26 | $-0.17 | +34.6% | $58M | +16.4% |
WGS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 1, 2026 | GARDNER MARK Aofficer: President | Grant | 35,441 | — |
| Jun 23, 2026 | Meister Keith A.director, 10 percent owner: | Grant | 4,248 | — |
| Jun 23, 2026 | Meister Keith A.director, 10 percent owner: | Option | 3,576 | — |
| Jun 23, 2026 | Leproust Emily M.director | Option | 3,576 | — |
| Jun 23, 2026 | Casdin Elidirector, 10 percent owner: | Grant | 4,248 | — |
| Jun 23, 2026 | Fuchs Thomasdirector | Grant | 4,248 | — |
| Jun 23, 2026 | PFENNIGER RICHARD C JRdirector | Grant | 4,248 | — |
| Jun 23, 2026 | Casdin Elidirector, 10 percent owner: | Option | 3,576 | — |
| Jun 23, 2026 | Leproust Emily M.director | Grant | 4,248 | — |
| Jun 23, 2026 | PFENNIGER RICHARD C JRdirector | Option | 3,576 | — |
| Jun 23, 2026 | Ryan Jasondirector | Option | 3,576 | — |
| Jun 23, 2026 | RUCH JOSHUAdirector | Option | 3,576 | — |
| Jun 23, 2026 | RUCH JOSHUAdirector | Grant | 4,248 | — |
| Jun 18, 2026 | Feeley Kevinofficer: CHIEF FINANCIAL OFFICER | Sell | 863 | $61.50 |
| Jun 18, 2026 | Stueland Katherinedirector, officer: CHIEF EXECUTIVE OFFICER | Option | 18,750 | — |
Source: WGS SEC Form 4 filings, latest Jul 1, 2026. For informational purposes only — not investment advice.
See the full WGS insider & 13F page →GeneDx Holdings Corp. company profile
Overview
GeneDx Holdings Corp. (NASDAQ:WGS) is a patient-centered health intelligence company founded by Eric Schadt in October 2015 and headquartered in Stamford, Connecticut. The company went public in November 2020 and has established itself as a leader in genetic testing, particularly in pediatric and rare disease genomics. GeneDx operates the Centrellis health intelligence platform, which applies artificial intelligence and machine learning to clinical and genomic data to build comprehensive models of human health and provide personalized medical insights.
Business
GeneDx operates in the genetic testing and genomic medicine industry, which involves analyzing patients' DNA to diagnose diseases, predict health risks, and guide treatment decisions. The company's core business revolves around exome and genome sequencing, sophisticated laboratory tests that read large portions of a patient's genetic code to identify disease-causing mutations. To understand GeneDx's products, it's helpful to know that human DNA contains about 3 billion letters of genetic code. An exome test reads about 1-2% of this code, focusing on the protein-coding regions where most disease-causing mutations occur. A whole genome test reads the entire genetic sequence. These tests are particularly valuable for diagnosing rare genetic diseases that affect children, where traditional medical approaches often fail to provide answers. GeneDx's primary revenue segments include: 1. Exome and Genome Testing (approximately 83% of revenue): This is the company's fastest-growing and highest-margin business, focusing on comprehensive genetic analysis for pediatric patients with suspected genetic disorders. The company has interpreted over 750,000 clinical exomes and genomes and holds an estimated 80% market share in U.S. commercial exome testing. 2. Traditional Genetic Testing (approximately 17% of revenue): This includes targeted gene panels and single-gene tests for specific conditions. The company is strategically reducing this lower-margin business by retiring approximately 350 tests to focus resources on higher-value exome and genome testing. 3. Data and Pharmaceutical Partnerships (approximately 5% of revenue): GeneDx leverages its vast genetic database to partner with pharmaceutical companies for drug development, patient identification for clinical trials, and disease research through its GeneDx Discover platform. The company primarily serves pediatric patients through outpatient clinics, with a particular focus on pediatric neurologists treating children with seizures, developmental delays, and other neurological conditions. GeneDx is also expanding into neonatal intensive care units (NICUs) with ultraRapid genome sequencing that can provide results within 48 hours for critically ill newborns.
Revenue model
GeneDx generates revenue primarily through fee-for-service genetic testing, where healthcare providers order tests for patients and the company bills insurance companies, government payers (Medicare/Medicaid), or patients directly. The average reimbursement rate for exome and genome tests is approximately $3,500 per test, significantly higher than traditional genetic tests. The company's customers are primarily healthcare providers, including pediatric neurologists, geneticists, and other specialists who order tests for patients with suspected genetic conditions. Insurance companies and government health programs are the ultimate payers, though patients may have out-of-pocket costs depending on their coverage. Several factors influence GeneDx's profitability margins. Positive margin drivers include the ongoing shift toward higher-priced exome and genome testing, improving insurance reimbursement rates as genetic testing becomes more accepted in medical practice, operational efficiencies from laboratory automation and AI-powered interpretation, and the company's dominant market position allowing for pricing power. The company has also been strategically reducing its test menu to focus on higher-margin offerings. Negative margin pressures include insurance claim denial rates (currently around 50% for some tests), which require additional administrative costs and may result in uncollected revenue. Competitive pressure from other genetic testing companies could potentially impact pricing, though GeneDx's market leadership position provides some protection. Additionally, the company faces ongoing investments in research and development, sales team expansion, and technology infrastructure that can pressure near-term margins. Changes in healthcare reimbursement policies or coverage decisions by major insurers could also significantly impact profitability. The company's business model benefits from strong recurring revenue characteristics, as satisfied customers tend to order multiple tests over time, and the clinical utility of genetic testing continues to expand into new medical specialties and conditions.
Competitive moat
GeneDx possesses a substantial competitive moat built on several interconnected advantages. The company's primary moat stems from its massive proprietary genetic database of over 750,000 interpreted clinical exomes and genomes, which creates a powerful network effect. Each additional test performed enhances the company's ability to interpret genetic variants and provide more accurate diagnoses, making their service increasingly valuable to healthcare providers. The company's data advantage is particularly strong in pediatric and rare disease genetics, where GeneDx has built comprehensive variant databases that competitors would find extremely difficult and expensive to replicate. This data asset becomes more valuable over time as the company sequences more patients and builds deeper clinical correlations. GeneDx also benefits from significant switching costs for healthcare providers. Physicians develop familiarity with GeneDx's reporting formats, interpretation quality, and customer service, making them reluctant to switch to competitors. The company's integration with major electronic health record systems like Epic further increases these switching costs. The company's market position provides additional protection, with an estimated 80% share of the U.S. commercial exome testing market. This dominance allows GeneDx to invest more heavily in research and development, clinical studies, and technology improvements than smaller competitors. However, the moat faces potential challenges. Large healthcare companies with significant resources, such as major laboratory service providers or technology companies, could potentially enter the market with substantial investments. Additionally, advances in AI and machine learning could potentially democratize genetic interpretation capabilities, though GeneDx is actively investing in these technologies to maintain its advantage. The company's moat is strongest in pediatric rare disease testing but may be more vulnerable as it expands into adult markets where other players have established positions.
Risks & safety
GeneDx demonstrates a moderate margin of safety with improving financial fundamentals but elevated valuation metrics. **Cash and Debt Position:** - Cash and short-term investments: $99.7 million (Q1 2025) - Strong current ratio of 3.25, indicating solid short-term liquidity - Debt-to-equity ratio of 0.45, representing manageable leverage - Positive free cash flow of $4.1 million in Q1 2025, marking a significant improvement from historical cash burn **Profitability Metrics:** - Achieved quarterly profitability in Q4 2024 with net income of $5.4 million - Positive EBITDA of $8.8 million in Q4 2024 - Gross margins improved to 70% in Q4 2024, up from 56% in prior year - Company expects to maintain quarterly profitability going forward **Valuation Concerns:** - Price-to-book ratio of 9.69 suggests premium valuation - Trading at high multiples despite recent profitability improvements - EV/EBITDA of 58.3x based on Q4 2024 positive EBITDA **Other Considerations:** - Revenue growth guidance of 30%+ for exome/genome testing provides visibility - Market leadership position in a growing industry provides some downside protection - Regulatory risks in healthcare reimbursement could impact future performance
Recent development
Over the past few years, GeneDx has executed a strategic transformation focused on portfolio optimization and market expansion. The company has systematically reduced its test menu by retiring approximately 350 lower-margin traditional genetic tests to concentrate resources on high-value exome and genome sequencing. This strategic shift has driven exome and genome testing from 16% of total test volume in 2022 to 40% in Q1 2025, with corresponding revenue growth of over 100% year-over-year. The company has made significant technological advances with the launch of ultraRapid whole genome sequencing capable of delivering results within 48 hours, specifically targeting neonatal intensive care units where rapid diagnosis can be life-saving. GeneDx has also integrated its testing services with Epic's electronic health record system through the Aura platform, streamlining physician workflows and reducing barriers to test ordering. Market expansion initiatives include moving beyond traditional pediatric neurology into new clinical areas such as immune deficiency disorders, cerebral palsy, and hearing loss. The company is also exploring the potentially transformative newborn genomic screening market through its GUARDIAN research study, which showed a 4% positivity rate in apparently healthy newborns. GeneDx has strengthened its pharmaceutical partnerships through the GeneDx Discover platform, which helps drug companies identify eligible patients for clinical trials and understand disease prevalence. The company has expanded from 20 to over 30 biopharma partnerships, representing a high-margin revenue stream with 70-90% margins. Recent strategic moves include the acquisition of Fabric Genomics to enhance AI-powered genomic interpretation capabilities and the decision to exit the hereditary cancer testing business in 2025 to focus resources on higher-growth opportunities. The company has also been investing in laboratory automation and AI technologies to improve operational efficiency and reduce costs.
WGS company profile · for informational purposes only — not investment advice.
Track WGS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free